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Abstract 
Worldwide, the prevalence of type 2 diabetes mellitus (T2DM) and its related management costs have increased over time. The latest 
predictions anticipate this trend to continue during the next few decades. As individuals with T2DM in the United States (US) are 
burdened with escalating prescription drug expenses, the appeal and use of cost effective alternatives may also increase. Herbal 
supplements are an example of such an alternative, but are unregulated and mostly lacking scientific evidence of advertised claims. In 
general, plant based herbal preparations are often advertised as ‘natural’, ‘less-toxic’, ‘medicines’ and are widely available from public 
retailers throughout the country. Over half of the US adult population report the use of supplements. Eastern countries, and especially 
China, have a long history of the use of herbal preparations as traditional medicine to prevent and treat diabetes. Recently the US has 
experienced a growth in the number imports of herbal supplements and other Traditional Chinese Medicines (TCM) to the country as 
well as the most rapid population growth in individuals who identify themselves as Asian. To date, little is known about the prevalence 
TCM use in the management of T2DM either alone or in combination with prescription medicines in the US. Knowledge of possible 
implications to patient safety (e.g., interactions, adverse effects) with concurrent use of both TCM and prescription medicines is also 
lacking. This review begins with summaries of the T2DM management strategies employed in traditional modern medicine (TMM) and 
Chinese medicine (TCM). A review of literature follows where the most commonly used TCM herbal preparations and their ingredients 
are identified and found along with any published reports of their proposed mechanisms of action, efficacy, adverse effects, and 
contraindications. 
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1.0 Diabetes: A Global Health Concern 
Diabetes is one of the largest and rapidly progressing global 
health concerns of the modern day era [1, 2].  The International 
Diabetes Federations predicts the number of individuals 
between 20 and 79 years of age with diabetes to increase from 
4.72 million in 2015 to 6.16 million by 2040 [2].  Being the most 
populous region of the world, China has the highest population 
of adults with diabetes, followed by India, and the United States 
(US) [2].  In China, the prevalence of adults with diabetes has 
risen approximately 10% since the late 1970s (i.e., from 0.67% 
to 11.6%) [3].  Even with lower rates of overall overweight and 
obesity, the Chinese and other individuals of Asian descent are 
particularly prone to develop diabetes earlier in life and at a 
lower BMI and waist circumference than European and Western 
individuals [4].  Such observations prompted the World Health 
Organization to redefine conventional definitions of overweight 
as BMI ≥ 25 kg m2 and obesity BMI ≥ 35 kg m2 to BMI ≥ 24 kg m2 
and BMI ≥ 28 kg m2  in Asians [5, 6]. 
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Other risk factors attributable to diabetes predisposition in 
Asian populations include a possible genetic susceptibility            
as well as increases in 1) overall and abdominal obesity,                  
2) abdominal and visceral adiposity for a given BMI,                           
3) westernization of diet and lifestyle/urbanization and food 
supply, 4) over-nutrition, 5) sedentary behavior, 6) cigarette 
smoking, 7) pancreatic beta cell dysfunction, 8) low birth 
weight.  
 
Beyond a considerable prevalence, the global economic burden 
of diabetes is also astounding.  In 2015, the US led the world in 
diabetes related health care related expenditures at 320 billion 
USD (320 Billion ID) followed by China at 51 billion USD (90 
billion ID) [2].  Since 1980, there has been fourfold increase in 
the number of Asians immigrating to the USA, the majority of 
which emigrated from China.  Currently, the most recent Census 
data (2010) shows the Asian population grew over 40%, faster 
than any other race group, over the last decade with almost six 
percent of the US population now identifying as Asian either 
solely or in combination with one or more other races [7].  With 
health care insurance and related costs continuing to rise, it is 
possible that more individuals may seek more cost effective 
options to manage their disease.  An easily accessible option in 
the US with cultural significance to a minority population 
experiencing the most rapid growth is Tradition Chinese 
Medicine (TCM).  
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2.0 Diabetes Management in Modern Medicine   
Type 2 diabetes mellitus (T2DM), the most prevalent form of 
diabetes, is the result of insulin resistance and a progressive loss 
of insulin secretion.  Once considered to be an ailment affecting 
only adults is now a worthy and concerning possibility in 
children and adolescents. This shift in representation is 
attributed to concomitant increases in obesity, diets lacking in 
fruit and vegetable consumption yet high in refined sugar, as 
well as increasing wealth, urbanization, physical inactivity, and 
changes in society and cultural norms [8].  
 
2.1 Screening and Diagnosis  
A number of risk factors for T2DM have been identified and are 
used to guide screening efforts in traditional modern medicine 
(TMM).  They include but are not limited to obesity, a sedentary 
lifestyle, cigarette smoking, a family history of T2DM, prior 
gestational diabetes, evidence of abnormal glucose 
metabolism, or being of Asian, Hispanic, or African-American 
descent.  Recommendations for screening exist to identify those 
at an increased risk of developing diabetes (i.e., prediabetes), 
as well as those with overt disease.  Fortunately, the same tests 
are used for both screening and diagnosis.  The routine 
screening of adults should begin at 45 years of age, regardless 
their body weight.  As well, any overweight (i.e., BMI ≥25 kg/m2 
or ≥23 kg/m2 in Asian Americans) adult regardless of age should 
also be screened.  Screening methods involve either the 
measurement a fasting plasma glucose (FPG), glycosylated 
hemoglobin (HbA1C), or else a two-hour 75g oral glucose 
tolerance test (OGTT),).  Those with a FPG ≥126 mg/dL, an A1C 
≥6.5%, or a plasma glucose of ≥200 mg/dL at two hours during 
a 75g OGTT meet diagnostic criteria for diabetes, while those 
with values between 100-125 mg/dL, 140-199 mg/dL, and 5.7-
6.4% respectively have impaired glucose tolerance, also 
referred to as prediabetic [9].  One other method of establishing 
a diagnosis of diabetes is based on the finding of a random 
plasma glucose ≥200mg/dL in an individual presenting with the 
classical symptoms of hyperglycemia [9]. Refer to Table 1 for a 
summary of diagnostic criteria.  
 
2.2 Medical Management of Type II Diabetes Mellitus 
Generally speaking, management consists of strategies to 
reduce hyperglycemia in order to prevent overt disease in those 
with impaired glucose tolerance, and complications in those 
with evidence of disease [10].  Effective glycemic control slows 
disease progression and significantly reduces the risk of long-
term microvascular, macrovascular, and neuropathic 
complications (e.g., retinopathy, nephropathy, neuropathy, 
peripheral vascular, and coronary artery disease) [11, 12].  As 
such, at the time diagnosis it is necessary to establish a current 
estimation of micro and macrovascular disease state or baseline 
on which future comparisons to gauge the efficacy of 
treatments can be made.  Assessments of an individual’s 
cardiovascular risk factors, (i.e., smoking status, lipid profile, 
blood pressure), baseline renal function, diabetic foot 
examination, ophthalmological examination should be 
completed.  
 
Subsequent management of T2DM in TMM necessitates 
individually tailored, multifactorial interventions involving a 
combination of approaches to self-management including 
educational, supportive, behavioral, nutritional, lifestyle, and 
pharmaceutical components.  Standards of medical care in 
diabetes are published on an annual basis that contain 
recommendations for glycemic targets upon which estimates of 
treatment efficacy can be made [13].  Though not telling of 
hypoglycemic events or glycemic variability in general, HbA1C 
does allow for estimation of the average blood glucose 
concentrations over the past several months and is predictive 
of diabetic related complications [14, 15]. The target HbA1C 
indicative of glycemic control and a lower risk of diabetes 
related microvascular complications in adults in <7%.  
Additionally, blood glucose self-monitoring is also useful as a 
means of assessing glycemic control however the timing, 
frequency, and specific goals of monitoring needs vary between 
individuals as well as selected treatments.   
 
2.2.1 Initial Strategies  
In TMM, the mainstay of preventative measures in those with 
prediabetes as well as the initial treatment in those with T2DM 
is a focus on knowledge provision and intensive lifestyle 
modification with specific goals of weight loss as appropriate, 
medical nutritional therapy, and 150 minutes of moderately 
intensive physical activity per week.  Intensive lifestyle 
modification is the initial management strategy used in modern 
medicine to reduce the prevalence of and initially manage 
T2DM [16-18].  Benefits of these types of interventions have 
been reported in group-based lifestyle interventions in both the 
residents of China as well as Chinese-speaking immigrants with 
prediabetes in the USA [16, 19].  The China Da Qing Diabetes 
Prevention Study found that the effects of a lifestyle 
intervention over a six-year span can prevent or delay diabetes 
for up to 14 years post-intervention.  As well, those who 
participated in the intervention spent 3.6 fewer years with 
diabetes than those who did not [16].  A randomized controlled 
trial by Yeh et al. (2016) examined the feasibility and 
acceptability of a community based, intensive lifestyle 
modification program in a sample of Chinese-speaking 
immigrants with prediabetes in New York City.  At 12 months 
post-intervention, intervention participants had lost 
significantly more weight and lower HbA1C, BMI, body fat 
percentage, and waist circumference [19].   
 
2.2.2. Pharmaceutical Strategies Used to Achieve Glycemic 
Control 
As depicted in Figure 1, when intensive lifestyle modification 
fails to result in adequate glycemic control, antihyperglycemic 
pharmaceutical interventions are added to the management 
regime until effect control attained [13].  Typically, 
monotherapy is initiated with Metformin.  Additional oral 
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hypoglycemic agents are subsequently added as needed when 
hyperglycemia persists after a three-month trial of a particular 
drug combination (i.e., 2-drug and 3-drug combinations).  
Should blood glucose levels remain refractory to a three-month 
trial of a 3-drug oral antihyperglycemic therapy, injectable 
antihyperglycemic therapies are used to achieve adequate 
control.   
 
2.3 Medical Management of Type II Diabetes Mellitus 
Comorbidities 
At the time of diagnosis, it essential to obtain baseline 
assessments for a number of comorbid conditions common in 
diabetic populations. These conditions typically involve micro 
and macrovascular predicaments that are often asymptomatic 
yet advanced at presentation and thus must be managed 
appropriately.  
 
2.3.1 Atherosclerotic Cardiovascular Disease Cardiovascular 
Disease Risk Factors   
Cardiovascular disease risk factors should be evaluated annually 
in T2DM.  Careful risk factor management strategies such as 
smoking cessation, low dose aspirin therapy, as well as blood 
pressure and lipid regulation reduces the likelihood of 
cardiovascular events.   
 
Hypertension 
Blood pressure should be measured at every clinic visit and 
hypertension managed with a treatment goal of 130-139/70-
89mmHg.  Angiotensin converting enzyme inhibitors (ACE-I) or 
angiotensin receptor blockers (ARB) are the drug of choice 
because as they have been shown to slow the progression of 
renal disease in hypertensive patients with moderately 
increased albuminuria (formerly called microalbuminuria) [20]. 
Substitutions with an alternative class of antihypertensive 
medication should be when there is ACE-I or ARB intolerance, 
though it is likely that multiple drugs may be needed to 
adequately control blood pressure.   
 
Lipid Management  
Lipid management is also a key component of T2DM 
management (see Tables 2 and 3).  The ADA suggests intensive 
lifestyle modifications to improve a patient’s lipid profile such 
as optimization of glycemic control; weight loss if indicated; 
reducing intake of saturated fat, trans fat, and cholesterol; 
increase intake of omega-3 fatty acids, viscous fiber, and plant 
stanols or sterols; and increasing physical activity [13].  Statin 
therapies are the mainstay medical management and 
recommended for most individuals with diabetes who are forty 
years of age or older.  Additional cardiovascular benefits occur 
with the addition of ezetimibine to moderately intensive statin 
therapy, recent acute coronary syndrome, LDL ≥50 mg/dL, or 
for those intolerant to high intensity statin therapy.  Men with 
triglyceride levels ≥204 mg/dL and a HDL ≤34 mg/dL may benefit 
from the addition of fenofibrate to statin therapy, but 
otherwise the combination of fibrates with statin are not 
recommended.  Neither is the combination of statins with 
niacin as due to an increased risk of cerebrovascular events.  
 
The mechanisms of actions, overall effects of, as well as factors 
pertinent to patient safety such as precautions, drug 
interactions, and adverse effects of antihyperglycemic and 
T2DM comorbid disease management pharmacotherapies are 
summarized in Table 2. 
 
3.0   Diabetes Management in Traditional Chinese Medicine  
3.0.1 Philosophy and Methods of Practice in Traditional 
Chinese Medicine  
Throughout history and across the globe, many countries 
developed their own methods of medical practices which were 
eventually acknowledged as their own practice of traditional 
medicine.   TCM has been used to treat the ailments of the 
peoples of Asia since ancient times and in fact was the only form 
of medical practice available in China until TMM was introduced 
by missionaries in the early nineteenth century. TCM employs a 
number of approaches to achieve a healthy body equilibrium 
founded on “syndrome” also known as “zheng” or “pattern” 
differentiation [21]. Zheng differentiation provides the 
conceptual basis on which TCM is built.  Zheng differentiation 
ultimately uses a combination of “symptoms, syndrome, and 
disease” to treat several chronic non-communicable diseases 
[22, 23].  
 
TCM practitioners use four examinations to assess the zheng of 
a patient [24].  The first examination focuses on the patient’s 
physique, skin complexion, and tongue condition.  The second 
involves listening to the patient’s voice to assess respiratory 
problems such a cough, phlegm as well as evaluating body odors 
suggestive of ill health.  Next, the practitioner will ask the 
patient how he or she feels overall in terms of their body 
temperature, perspiration, bowel movements, and thirst etc.  
Finally, palpations of pulses are used to indicate overall health.  
The cumulative findings of such examinations suggests a 
pattern of zheng that establishes a diagnosis and in turn 
treatment options to resolve underlying problems.  Treatment 
options commonly used in TCM include, but are not limited to 
the following therapies: herbal medicines, acupuncture, heated 
cup therapy (cupping), massage therapy (tuina), movement and 
breathing exercises (qigong), and burnt mogwort therapy 
(moxibustion).   
 
3.0.2 Xiaoke  
TCM has been used to treat DM for more than 2000 years [23, 
25].  Initially, practitioners created a word to distinguish a 
cluster of typical symptoms when diabetes was first observed in 
ancient China “Xiaoke”  [26].  Traditional Xiaoke disease 
was based on a syndrome or zheng pattern of “three excess and 
one loss” of the classical presentation of T1DM, excessive thirst, 
excessive urination, excessive food consumption, and weight 
loss.  The underlying pathological process was believed to be an 
initial deficiency in yin leading to dryness body heat at times 
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accompanied with phlegm retention and blood stasis.  A 
prolonged yin deficiency was thought to impair yang leading to 
qi insufficiency and ultimately leading to a dual deficiency of qi 
and yin as well as yin and yang.  With these beliefs, TCM tenets 
involve a nourishment of yin with bitter flavors or cold property 
to enhance qi while clearing of heat from the body promoting 
fluid production [27-29].   
 
Recently with the escalation of T2DM, there is evidence that the 
zheng of “three excess and one loss” remains only somewhat 
applicable to T2DM as half of T2DM patients are asymptomatic 
initially while 80% of those with symptoms present atypically 
[30]. It is thought that the excesses and loss syndrome typifies 
more advanced disease as practitioners are now often 
diagnosing T2DM prior to the appearance of “three excess and 
one loss” through physical examination and other biometric 
indicators especially in suspect individuals with obesity and/or 
central adiposity [30, 31].  Investigators have recently 
acknowledged that early and middle stage disease is better 
represented with a spleen-warm syndrome referred to as “Pi 
Dan” a direct result of inactivity and an abundance of food 
consumption.  Pi Dan is thought to be caused by an 
overstimulation of the gastrointestinal tract through too much 
food consumption leading to excesses in splenic, stomach, liver, 
gall bladder, and intestinal heats.  Similar in TCM pathogenesis 
evidence of effective management through yin nourishment 
using herbal preparations with bitter flavor or cold property 
characteristics [31].   
 
While the philosophy and occupations of TMM and TCM are 
unalike leading to different methodologies in the diagnosis and 
treatment of T2DM, there are a few similarities such as the 
application of nutrition and exercise as treatment modalities.  
As in TMM, lifestyle interventions in Chinese individuals 
involving diet and exercise can prevent or delay the progression 
of prediabetes to T2DM [16].  Without lifestyle intervention, 
within 20 years approximately 90% of those with prediabetes 
progress to T2DM and 50% experience at least one 
cardiovascular event.   
  
3.1 Xiaoke Review of Literature  
TCM uses approximately eight hundred different plants and 
herbs as natural medicines to prevent and treat Xiaokezheng 
[29].  TCM providers will either give patients a single herb 
extract, or more often than not a complex formulation of 
multiple extracts and compounds with the idea of targeting 
multiple physiological mechanisms within the body to treat 
T2DM.  Unlike TMM where antihyperglycemic medicines 
typically employ one mechanism of action to lower PBG 
concentrations, TCM practitioners and researchers proposed 
that TCM formulations and even single herb preparations often 
employ a number of mechanisms of action concurrently to do 
the same [27, 31].  For instance, a review by Wang et al. (2013) 
proposed that Xiaoke TCM herbal plant extracts used at least 
one of seven different mechanisms of action many of which act 
at the same site or on the same physiological pathway as some 
of the TMM outlined in Figure 1 [27].  As depicted in Figure 2, 
itemized the mechanisms of actions were as follows: 1) 
decreased carbohydrate absorption, 2) improved insulin 
sensitivity, 3) increased peripheral glucose uptake, 4) stimulate 
insulin secretion, 5) potentiate endogenous incretins, 6) 
antioxidant effects decreasing cellular apoptosis, and 7) 
increased glycogenesis or inhibition of hepatic glycogenolysis 
[27].  
 
Consequently, the aforementioned multiple concurrent 
mechanisms of actions compounded by inherent difficulties in 
the quantification of chemical compositions and concentrations 
of each herb added to a complex formulation that has 
somewhat hindered the widespread use of TCM as a 
complementary and alternative medicine (CAM) in TMM.  Along 
these lines, there have also been difficulty determining the 
therapeutic efficacies of various TCMs due to practitioner 
variations in preparation techniques and applied doses given to 
patients based on their evaluations of Xiaoke syndrome 
differentiation.  One final contemplation that could quite 
possibly be hindering implementations of TCMs into TMM lies 
specifically within a considerable priority in the provision of 
healthcare in the western world, patient safety and quality 
assurance.  At present, little is known about the possibility of 
interactions between or adverse effects of simultaneous 
combinations of TCM formulations with and commonplace 
TMMs.   
 
3.1.1 Xiaoke Formulations 
In 2007, the China Association of Chinese Medicine published 
the first set of guidelines adopted by TCM primary care 
physicians in China concerning the prevention and treatment of 
DM using TCM.  Herbal medicines with bitter flavor and cold 
property have evidence of effective treatment applications.  A 
synopsis of the most common TCM herbal 
preparations/concoctions used to treat T2DM is presented 
below.  When provided, proposed mechanisms of actions, 
overall effects of, as well as factors pertinent to patient safety 
such as precautions, herb/drug interactions, and adverse 
effects will be included in the review.   
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Tianqi 
Tianqi is a novel Chinese herbal medicine used to treat T2DM in China [32-34].  Tianqi’s herbal quality and decoction 
preparation is regulated by the Chinese Pharmacopoeia.  It is manufactured in capsule form by the Heilongjiang Baoquan 
Pharmaceutical Company and contains ten herbal medicines.  
Ingredients: Astragali Radix   
Coptidis Rhizoma berberine 
Trichosanthis Radix 
Ligustri Lucidi Fructus 
Dendrobii Caulis 
Ginseng Radix 
Lycii Cortex 
Ecliptae Herba 
Galla Chinensis 
Corni Fructus 
Proposed MOA of the concoction: not specified 
Overall effects:  
- overall reduction in risk for diabetes of 32.1% [32]. 
- Reduced HbA1C by 1.15%±1.58% [33] 
- Reduced pre- and 2-hour post prandial blood glucose [33] 
In a multicenter randomized controlled trial by Lian et al (2014), individuals with impaired glucose tolerance were 
given five capsules thrice daily before meals of either a placebo or Tianqi (1.6g capsules) for twelve months.  The 
contents of the marker compounds in the Tianqi capsules used in this study were as follows: magnoflorine (0.04±0.01 
mg/g), berberine (2.14±0.07 mg/g), gallic acid (21.39±0.12 mg/g), astragaloside IV (0.07±0.01 mg/g), palmitic acid 
(3.55±0.08 mg/g), ginsenoside Rc (0.31±0.01 mg/g), ginsenoside Rd (0.60±0.02), and ginsenoside Re (0.25±0.01). At 
the end of the study there were no statistical differences in body weight or body mass index changes between the 
two groups.  No serious adverse events were reported, and the common events were related gastrointestinal matters 
(i.e., nausea, flatulence, constipation, diarrhea).  Significantly more subjects developed T2DM in the control group 
(29.32%) than the Tianqi group (29.32% vs. 18.18%; p=0.01) which reflected an overall reduction in the risk of T2DM 
development by 32.1% [32]. HbA1C and plasma insulin were not assessed.  
An observational study by Zhao et al. (2003) reported a reduction in HbA1C by 1.15%±1.58% as well as pre- and 2-
hour post prandial blood glucose levels in 300 individuals with T2DM following 8 weeks of Tianqi ingestion.   
Patient Safety: 
- Proposed “similarity in efficacy”:   
 α-glucosidase inhibitor (acarbose) 
 metformin 
- Adverse effects:  
 gastrointestinal 
 (<1%) rash, weakness, weight loss, polyuria, tinnitus, CBC abnormalities 
- Interactions: unknown  
- Precautions: unknown 
 
Kaiyu Qingre Fang (aka Kaiyu Qingre-Jiangzhao or Kaiyuqingre) 
Kaiyu Qingre Fang is used to treat diabetes by nourishing yin with bitter flavor and cold to enhance qi while clearing heat 
form the body [30, 31, 35, 36].   
Ingredients: Scutellariae [35] 
Rhizoma Coptidis berberine [35] 
Chinese Rhubarb [31, 35] 
Momordica Charantia  [31]  
Anemarrhena [31] 
“and so on” [31] 
Proposed MOA of the concoction:   
- improve late phase beta cell secretion of insulin [36] 
  - contribute to insulin resistance [36] 
- reduce fatty acid synthase activity by modifying overexpression of sterol regulatory element binding 
protein-1c to modulate glucose and lipids [37, 38] 
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Overall Effects:  
- decreased HbA1C by 1.32% [35] 
- decreased HbA1C by 1.67% [22, 39] 
- “similar to metformin for decreasing glucose “but safer” [22, 39] 
In a multi-centered RCT including both TCM and western medicine hospitals in Beijing (n=127) by Lian et al (2008) a 
control group received metformin and the treatment group received Kaiyu Qingre-Jiangzhuo (KQJ) for 12 weeks.  
Significant reductions in FBG, P2BG at 4-, 8-, 12-12 weeks as well as HbAlc of 12-weeks were observed in both groups 
from baseline values (p<0.05).  There were not statistically significant differences between the two groups and no 
adverse effects were reported in the KQJ group.   
Patient Safety: 
- Proposed “similarity in efficacy”:   
 similar to metformin “but safer” [22, 39] 
- Adverse effects: none reported 
- Interactions: unknown 
- Precautions: unknown 
 
Tang-Min-Ling-Wan (TM81)  
This is another concoction used to treat T2DM by feeding yin with cold property and bitter flavor [31, 40].  
Ingredients: Rhizoma Coptidis   berberine shall not be <6.0mg/g [40] 
Chinese Rhubarb [40] 
Radices Trichosanthis  [40] 
Radix Paeoniae Alba paeoniflorin shall not be <3.0 mg/g [40] 
Radix Scutellariae [40] 
Pericarpium Cirtri Reticulatae [40] 
Rhizoma Rhei [40] 
“and other Chinese herbs” [40] 
Major compounds: berberine, albiflorin, paeoniflorin, naringin, hesperidin, baicalin 
Proposed MOA of the concoction:  
- triggers insulin secretion in a high glucose environment [40] 
- similar to rosiglitazones ability to improve insulin secretions by islet cells by significantly increasing 
PPARα [41] 
- reversion of insulin resistance  
 Effects:  
- decreased HbA1c BY 1.18%  [40] 
- lowers blood glucose levels (HbA1C, FPG, 2hPG) 
- reduces WC and BMI and obesity 
- increases β-cell functioning  
In a multicenter randomized controlled trial, Tong et al (2013) compared the effects a twelve-week regimen 
of thrice daily oral ingestion of 6g TM81 to a placebo group in individuals with early stage T2DM in China 
[40].  Authors note that the content of berberine in Rhizoma Coptidis was not less than 6.0mg/g and 
paeoniflorin in Radix Paeibuae Alba less than 3.0 mg/g in the final product.  At the end of the study the mean 
HbA1C decreased by 1.02% and 0.47% in the treatment and control group respectively (p<0.001).  FPG 
decreased by 0.8 ±0.1mM in the TM81 group and increased 0.2±0.2mM increase in the control group. HbA1C 
decreased 1.0±0.7% in the TM81 group versus 0.2±1.0% in the control group (p<0.001) with.  Significant 
differences were found in terms of 2hPPG, body weight, BMI, T2DM symptoms, waist circumference, insulin 
resistance (HOMA-IR), β-cell functioning (HOMA-β), triglyceride, total cholesterol, HDL, and LDL favoring 
improved values in the TM81 versus control group. There were no significant differences in the adverse 
reactions reported between the two groups.  
Patient Safety: 
- Proposed “similarity in efficacy”:  none reported 
- Adverse effects: no significant differences between TM81 and control group 
- Interactions: unknown 
- Precautions: unknown 
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Gegen Qinlian Tang (aka Gegen Qin Lian) 
Gegen Qinlian Tang is another common TCM preparation used to treat diabetic individuals with damp heat syndrome of the 
spleen through yin nourishment with bitter flavor and cold to enhance qi while clearing heat form the body [31, 42, 43].   
 Ingredients:  
- Radix Puerariae (Ge Gen)    24g, 72g, 120g [43]     1.0g, 24g, 72g, 120g[44] 
- Radix Scutellariae (Huang Qin)    9g, 27g, 45g   [43]     0.4g, 9g, 27g, 45g    [44]  
- Rhizoma Coptidis (Huang Lian)    9g, 27g, 45g   [43]     0.4g, 9g, 27g, 45g    [44]  
- Radix Glycyrrhizae (Zhi Gan Cao)   6g, 18g, 30g   [43]       
- Rhizoma Zingiberis (Gan Jiang)        1.5g, 4.5g, 7.5g  [43]   
- Honey-fried Licorice Root (Gan Cao)    0.3g, 6g, 18g, 30g    [44] 
- Fructus Ziziphi Jujubae (Chao Zao Ren) was added for insomnia [43] 
- Jiu Da Huang (Radix et Rhizoma Rhei) was added for constipation [43] 
- Spika Prunellae (Xia Ku Cao) was added for liver-yang hyperactivity [43] 
- Rumulus Uncariaecum Uncis (Gou Teng) was added for liver-yang hyperactivity [43] 
- Hong Qu (Semen Orysae cum Monasco) was added for high blood lipid [43] 
- Wei Ling Xian (Radix Clematidis) was added for high uric acid [43] 
Proposed MOA:   
- reduces glucose metabolism disorders [31] 
- reduces insulin resistance [31] 
- increases tissues sensitivity to insulin [31] 
- improves physiological antioxidant functions [31] 
- protects pancreatic function [31] 
- induces structural changes in gut microbiota (i.e., increases beneficial bacteria Faecalibacterium spp.) 
[44] 
 Effects:  
- reduced glucose by 91% [45, 46]  
- 12 weeks (high dose reduced HbA1C by 1.79±0.11[43] 
- 12 weeks high dose reduced: [44] 
 FPG 1.46±0.23 
 HbA1C 0.88±0.14 
 HOMAβ 
Tong et al. (2011) examined the effects of two daily oral doses of low, medium, and high doses of Gegen Qin Lian 
taken on an empty stomach once in the morning and once in the evening for a total of 12 weeks.  Pre- and post-  
FPG, postprandial blood glucose, and HbA1C were measured in the 54 participants.  The overall effective rate of 
blood glucose control of high dosage, medium dosage and low dosage group were 80%, 47%, 30% respectively, 
and there were significant differences between high dosage group and low dosage group. The decrease of FBG, 
PBG and HbA1C of high dosage showed significant differences from low dosage too. No placebo/control group.  
Hepatic and renal function remained unchanged from pre to post intervention.  Reported adverse effects were 
stomachache with postprandial versus preprandial high dose administration and constipation with medium 
dose.  
 
Xu et al. (2015) In a randomized, double-blinded, placebo controlled clinical trial, Xu et al (2015) examined the 
1) efficacy and safety of GQD in the treatment of T2DM, and 2) the structural alterations of gut microbiota in 
response to GQD treatment. GDP was administered in twice-daily oral, pre-prandial doses. GDQ treatment 
provided dose dependent and clinically meaningful reductions in FPG, HbA1C, HOMAβ, as well as alterations in 
gastrointestinal microbial composition. Adverse events/effects were not reported anywhere within the article.  
Patient Safety: 
- Proposed “similarity in efficacy”:   
 Sulfonylurea [47, 48]   
 Buiguanides [47, 48]   
- Adverse effects:   
 stomachache with postprandial (versus pre-prandial) high dose (n=1)[43]  
 constipation medium dose (n=1)[43] 
- Interactions: unknown 
- Precautions: unknown 
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3.1.2 Xiaoke Common Single Ingredients   
The previous section reviewed the four most common 
concoctions used in TCM to treat Xiaoke.  Though much of the 
TCM research has focused on preparations involving multiple 
ingredients, there is some evidence of single ingredient 
considerations.  Of the four most common TCM preparations 
identified in the section above, there were several single 
ingredient commonalities.  Specifically, rhizoma coptidis was 
found in all four formulations and scutellariae was found in 
three.  What follows are in depth reviews of the literature for 
these two herbs.   
 
Rhizoma Coptidis (Huang Lian)  
The primary active ingredient in rhizoma coptidis is berberine [49].  Berberine is a natural plant alkaloid isolated 
from the Chinese her coptis chiesnensis (huanglain).  
Main Ingredient: berberine (an isoquinoline alkaloid) 
Proposed Mechanisms of Action:  
- reduces glucose metabolism disorders 
- reduces insulin resistance 
- increases tissue sensitivity to insulin 
- improves physiological antioxidant functioning 
- protects pancreatic function 
- increases insulin receptor expression (in vitro and in animal models) 
- significantly improves insulin signaling 
- “insulin sensitizer” in peripheral tissues via protein kinase C-dependent insulin receptor upregulation 
 Effects:  
- reduced glucose by 0.9% [50] 
- 90% effective in reversing DM with few side effects [51] 
- Same effects as metformin and rosiglitazone on reducing glucose and HbA1C 
- More effective at lower lipids than (above)  
- Can be used with hepatic insufficiency [52, 53]  
- A randomized double-blind, placebo controlled and multiple center trial by Gu et al. (2010) found 
significant improvements in fasting and 2-h OGTT plasma glucose and in HbA1C, serum total cholesterol, 
triglycerides and LDL-c concentrations after a 12 week berberine treatment compared to the control 
(placebo) group. Berberine, a constituent of Coptidis Rhizoma, was reported to improve glycemic 
parameters, including glycosylated hemoglobin (HbA1C) and FPG (9–11 of Lian 2014). 
 Other effects:   
- antimicrobial effects against staphylococcus aureus, methicillin resistant staph aureus, and candida 
[54, 55] 
- antiprotozoal effects again entamoeba histolytica, giardia lamblia, trichomonas vaginalis [54, 55] 
- enhances antimalarial effects of drugs in chloroquine resistance strains [54, 55] 
- antidiarrheal activity [55] 
 
Patient Safety: 
- Proposed “similarity in efficacy”:   
 metformin, rosiglitazone with greater effects of reducing lipids [31] 
 “similar in efficacy to sulfonylureas and biguanides” [47, 48] 
- AE: none reported, “safe” for patients [52] 
- Interactions: none reported 
- Precautions: none reported 
- Other Proposed Uses of Huang Lian in TCM   
 Gastrointestinal concerns: Dysentery, vomiting, epigastric “stuffiness” 
(liver/jaundice, eczema, gall bladder, bladder) 
 Cardiovascular, stomach, and liver concerns 
 Insomnia 
 Mouth or tongue sores 
 Abscesses, furuncles, carbuncles 
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Radix Scutellariae (Huang Qin), Scutellaria Baicalensis Georgi 
 Main Ingredient: wogonin (5,7-dihydroxy-8-methoxyflavon)  
Proposed Mechanisms of Action:  
- enhances peroxisome proliferator-associated receptor (PPAR) α isoforms and adiponectin expression 
through AMP-activated protein kinase (AMPK) activation 
- suppress osteopontin (OPN) expression [56]   
- improves cardiac function in diabetic cardiomyopathy 
Effects:  
- improve insulin sensitivity 
- reduces fasting blood glucose 
- ameliorates glucose tolerance 
- Improves cardiac function in diabetic cardiomyopathy 
 
 Other effects:  
- Anti-cancer effects anti-inflammatory, anti-apoptosis, and anti-allergic properties [57-61] 
- scavenges reactive oxygen species  
- attenuates nuclear factor kappa-light-chain-enhancer of activated B cell activity 
- inhibit several genes important for regulation of the cell cycle responsible for cytostatic 
effects 
- suppresses cyclooxygenase (COX-2) gene expression 
- prevents viral infections  
- selectively induces apoptosis in tumor cells with minimal or no toxicity in normal cells   
Patient Safety: 
- Proposed “similarity in efficacy”:  none reported 
- AE: none reported  
- Interactions: none reported 
- Precautions: none reported 
- Other Proposed Uses of Huang Qin in TCM   
 Relieves heat from high fever, abscesses, sores, sore throat 
 Stops bleeding (blood cooling and bleeding stopping herb) in hematemesis, 
hemoptysis, melena, hematuria, metrorrhagia, epistaxis 
 Abortion prophylaxis 
 
 
Table 5 catalogs claims found within the literature relating to 
the proposed mechanisms of action, precautions, and adverse 
effects of five other herbs found in the most common TCM 
herbal preparations identified in section 3.1.1.  
 
4.0 Future Directions 
The popularity of TCM use has escalated and herbal 
preparations are now widely available and used throughout 
USA, Europe, and Australia.  In 2010, the US was the biggest 
importer of TCM articles from China having spent over 7.5 
billion dollars on product.  According to the CDC, approximately 
38% of US adults use some form of Complementary and 
Alternative Medicine (CAM) with the most utilized therapy 
being non-vitamin, non-mineral natural products [62].  In the 
US, TCM herbal preparations or supplements are considered a 
form of CAM or even at times a nutritional supplement, but are 
for the most part unregulated by the Food and Drug 
Administration (FDA).  Such ambiguity and paucity in the 
regulation of TCMs evokes ruminations of the hazards and ill 
effects of ingesting unknown and unregulated substances [63].   
 
Beyond this obvious avenue of thought, there is also a lack of 
quality research to establish the possible clinical efficacies and 
safety profiles of TCMs.  Clinical trials comparing the 
effectiveness of TMMs to TCMs in diabetes management are 
thus justified and warranted. Should these trials of 
comparative effectiveness find certain TCMs to be inferior or 
even superior to the TMMs detailed in current T2DM clinical 
practice guidelines, support for the credibility of TCMs would 
be attained and may even facilitate the approval of Xiaoke 
herbal medicines by the FDA.  
 
At present, some research scholars divulge differing opinions 
about the manner in which TCMs should be implemented in 
clinical trials of efficacy and even the use of TCM in the modern 
era in general.  Some scholars are certain that TCMs should be 
quantified, certified and regulated using the rigorous processes 
that led to the approvals of TMMs for use in the treatment of 
T2DM in the US, while others trust TCMs should be adopted 
consistent with the underlying philosophy and methods of 
practice in TCM as described beforehand.  In other words, what 
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is otherwise understood as lack of regulation or vagueness in 
the doses and compositions of TCM prescriptions and therapies 
by some parties has actually initiated the announcements of a 
number of future research foci.  For instance, the World Health 
Organization recognizes a need to identify underlying 
mechanism of actions in TCM ingredients and has subsequently 
endorsed an international agreement to support the safe and 
effective use of TCM within established health care systems of 
its member states [64].  In time, this will result in TCM 
preparations becoming as formally defined as TMM medicines 
(i.e., quantification, clinical efficacy, dosing, pharmacokinetics, 
pharmacodynamics, adverse effects, precautions etc.) prior to 
their use in its member states.  Such formal definitions of TCMs 
may generate a wider acceptance of TCM in medical practices 
in western civilizations.  Conversely, the Chinese government 
and its research community are continuing efforts to regulate 
traditional herbal medicines just as they evolved from their 
underlying philosophical system and subsequently 
implemented in medical practices to treat diabetes for 
thousands of years.  China’s FDA promulgated a 2015 edition of 
the Chinese Pharmacopoeia that promotes the utilization, 
production, and supervision of Chinese drugs with intent to 
ensure drug safety and effectiveness for its public [65]. 
 
Irrespective of the approach used to implement TCMs in clinical 
trials of efficacy, we are of the opinion that the most imperative 
outcome is effective management of T2DM.  Therefore, in 
addition to ultimately supporting those medicines with 
established clinical efficacy, we advocate for international 
research collaborations and overall global capacity building.  In 
doing so, it is entirely possible that in the future, a combination 
T2DM management strategy from both Chinese and western 
medical practices may be most effective.  In fact, a number of 
Chinese researchers have already proposed theories describing 
how TCM and TMM can be implemented together to manage 
diabetes and its sequelae across the disease spectrum [27, 30, 
66].   
 
Much more troublesome than the different operational 
approaches to TCM employed in clinical trials is the limited 
knowledge of the potential implications of the concurrent use 
of TCM and TMM in those who require multiple TMMs to 
effectively manage a chronic non-communicable disease such 
as diabetes.  Encouraged by concerns of patient safety and the 
provision of quality healthcare in the US, we suggest that 
research efforts begin with initial and continued careful 
evaluations of those who concurrently use TMM, TCM, and 
other nutritional supplements with particular attention paid to 
those with T2DM using five or more TMM medications.  
Programs associated with patient safety such as Patient Safety 
Organizations (PSO) are uniquely poised to easily complete 
these types of evaluations and detect any safety related 
concerns with concurrent uses of TMM and TCM.    
With pragmatic approaches to document the comparable 
efficacies of TCMs as well as the prevalence, incidence, and 
evaluations of the effects of concurrent uses of TMM and TCM 
use in T2DM identified, we can now contemplate other 
matters.  Earlier we alluded to a possible attractiveness of TCM 
use in T2DM due to its affordability especially when compared 
to the increasing costs of TMM, health care insurance, and 
other health care related costs.  We also mentioned the 
cultural significance of TCM to individuals of Asian descent who 
are predisposed to T2DM.  The spectacular increase in the 
number of Asian immigrants to the US in the past few decades 
highlights an important research opportunity in a targeted 
population.  New York City has one of the highest Asian 
American populations within the US.  Previous research has 
documented the feasibility of data collection in this population 
within this context.  For example, the New York City Health and 
Nutrition Examination Survey found that almost half of the NYC 
Asian Americans had prediabetes or diabetes at a lower relative 
body weight than other population groups [67].  Thus, research 
about T2DM in Asian American populations in NYC is feasible.  
Given their access to a variety of culturally acceptable means 
of blood glucose control, documentation of their TCM use is an 
admirable opportunity.   
 
It is well known that upon arrival to the US, immigrants are 
often healthier that those born in the US with lower body mass 
indexes, higher fruit and vegetable consumptions, and higher 
levels of certain physical activities [68-75].  An explanation for 
these health advantages in first generation immigrants is their 
maintenance of the cultural beliefs stemming from their 
country of origin.  Another beneficial outcome of research 
relating to the use of TCM in Asian American populations is 
documentation of second, third, fourth etc. generation 
immigrants that have likely become ‘westernized’.  In other 
words, subsequent generations of immigrants to the US are 
likely exposed to the cultural beliefs of their family’s original 
countries of origin however; their belief systems may have 
been ‘Americanized’.  Support for this theory comes from 
evidence of associations of the duration of time spent in the US 
with overweight and obesity.  For example, both Chinese and 
Filipino immigrants living in NYC for longer durations had 
higher overweight and obesity risks [76, 77]. 
 
The concept of ‘Americanization’ allows for the speculation of 
a further value to research documenting TCM use in America.  
Race and ethnicity are known as risk factors for T2DM.  In 
addition to some Asian Americans, other minorities also have a 
higher risk of T2DM than Caucasians such as African Americans, 
Hispanics and Latinos, American Indians, and Pacific Islanders.  
Nevertheless it remains unknown to what, if any, extent these 
minorities use TCMs or other economical dietary supplements 
with hopes of controlling their prediabetes or diabetes [78].  
According to National Health and Nutrition Examination Survey 
data, over half (52%) of those surveyed reported the use of a 
dietary supplements in the preceding 30 days [79].  With such 
a large percentage of Americans reporting the use of dietary 
supplements and the Centers for Disease Control and 
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Prevention actively working to reverse the epidemic of 
diabetes in the US, further understanding is warranted.  
 
The principal objective of the current article was to initiate our 
understanding of TCM by identifying and summarizing existing 
literature on the most common TCM Xiaoke preparations and 
disease management strategies from a TMM perspective. TCM 
researchers and practitioners have made similar efforts to 
disseminate knowledge concerning their applications of herbal 
treatments in diabetes so that “the Western people know more 
about anti-diabetic TCM” [31].  The current article also 
discussed fundamental differences between the two 
approaches to medicine in terms of their underlying 
philosophies, theories, and methods of practice as these 
differences are often cited as reasons as to why their 
concurrent practice is problematic. It is our hope that 
continued discussions such as this will facilitate global 
partnerships with the same research agendas.  Ensuring the 
safety and efficacy of TCM requires a great deal of research that 
could be completed in a timely manner through international 
collaboration.  Therefore, it is important for researchers across 
the globe to first understand each other in order to work 
together effectively toward a common goal while ensuring 
patient safety.    
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Table 1. 
Criteria for the Diagnosis and Prediabetes and Diabetes 
Variable Prediabetes Diabetes 
Hemoglobin A1C (%) 5.7-6.4 ≥6.5 
Fasting plasma glucose level     
     mmol/L 
     mg/dL 
 
5.6-6.9 
100-125 
 
7.0 
≥6.5 
Oral glucose tolerance test results*  
     mmol/L 
     mg/dL 
 
7.8-11.0 
140-199 
 
11.1 
≥200† 
Random plasma glucose level 
     mmol/L 
     mg/dL 
 
- 
- 
 
11.1 
≥200‡ 
* 2h plasma glucose level after a 75g oral glucose tolerance test 
† In the absence of unequivocal hyperglycemia, results should be confirmed by repeated testing.  
‡ Diagnostic only in a patient with classic symptoms of hyperglycemia or hyperglycemic crisis.  
Note. Reprinted from “Diagnosis and Management of Diabetes: Synopsis of the 2016 American Diabetes 
Association Standards of Medical Care in Diabetes.” by J. J. Chamberlain, A. S. Rhinehart, C. F. Shaefer, and A. 
Neuman, 2016, Annals of Internal Medicine, 164, p. 543.  Copyright © 2016 American College of Physicians.  
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Table 2. 
Pharmacodynamics and important patient safety related factors of common T2DM treatments. 
 Mechanism of Action  Precautions Adverse Reactions 
Metformin - Inhibits hepatic 
gluconeogenesis 
- Decreases intestinal 
absorption of glucose 
- Enhances peripheral muscle 
glucose uptake and utilization 
 
Precautions: 
- eGFR<60 
- metabolic acidosis 
- lactic acidosis 
- dehydration 
- sepsis 
- surgery 
- DKA 
- Hepatic impairment 
Cautions: 
- CHF 
- Elderly 
- Alcohol abuse 
- Hypoglycemia risk 
- eGFR<60 
- Discontinue prior to iodinated 
contrast imaging 
 
- GI (diarrhea, nausea, 
vomit, flatulence, 
indigestion, abdominal 
discomfort, anorexia, 
metallic taste) 
- Rash 
- Headache 
- Asthenia 
- Ovulation induction 
- Lactic acidosis 
- Megaloblastic anemia 
 
Sulfonylureas 
Glyburide 
Glipidize 
Glimepride 
Acetohexamide 
Chlorpropramide 
Nateglinide 
rosiglitazone 
Tolazamide 
Toblutamide 
Torsemide 
- Insulin secretagogue 
- Stimulates pancreatic islet 
beta insulin release 
- Increase insulin receptors in 
peripheral tissues 
Precautions: 
- Hypersensitivity (class, 
sulfonamides) 
- DKA 
- T1DM 
Cautions:  
- Elderly 
- Hearing impairment 
- Hepatic impairment 
- Acute MI 
- Arrhythmia  
- renal impairment (hypoglycemia) 
- malnutrition 
- G6PDs 
- Diarrhea 
- Nausea 
- Hypoglycemia 
- Dizziness 
- Nervousness 
- Tremor 
- Rash 
- Headache 
- Drowsy 
- Photosensitivity  
- Hypoglycemia 
- Leukopenia 
- Thrombocytopenia 
- Hemolytic anemia 
- Rash 
- Purpura 
- Pruritus 
- Antithyroid activity  
- Diffuse pulmonary 
reactions 
- Mild diuresis 
- Fluid retention 
- Nausea, vomit, cholestasis 
- Agranulocytosis 
- Hepatitis 
- Hepatic failure 
- Hyponatremia 
- Disulfiram-like effect 
- SIADH 
- Aplastic anemia  
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Thiazolidinediones 
Pioglitazone 
Rosiglitazone 
 
- Reduces insulin resistance in 
peripheral tissue via PPAR 
gamma system 
- Enhances insulin action in 
muscle, liver, fat tissue 
(insulin sensitizer) 
- Lipid lowering, mild 
antihypertensive, decreases 
hepatic glucose effects 
Precautions:  
- Pediatric 
- T1DM 
- DKA 
- Active bladder cancer 
- CHF (symptomatic or NYHA Class 
III-IV) 
Cautions:  
- CHF (risk of, NYHA Class I-II) 
- Edema 
- hepatic impairment 
- PMH bladder cancer 
- female 
- URTI 
- Headache 
- Myalgia  
- Edema 
- Weight gain anemia 
- Ovulation induction 
- CHF 
- Hepatotoxicity 
- DM macular edema 
- Bladder cancer (long term 
use) 
- Fractures (female) 
 
Dipeptidyl Peptidase 4  
(DPP-4) Inhibitors 
Sitagliptin 
Saxagliptin 
Linagliptin 
alogliptin 
 
- Inhibits dipeptidyl peptidase-4 
- Slows incretin metabolism 
- Increases insulin 
synthesis/release 
- Decreases glucagon levels  
- Prolongs the action of incretin 
hormones (GLP-1, GIP) 
 
Precautions:  
- Hypersensitivity 
- T1DM 
- DKA 
Cautions:  
- Pancreatitis 
- CrCl <50 
 
- URTI  
- Headache 
- Diarrhea 
- Abdominal pain 
- Arthralgia 
- Hypersensitivity  
- Anaphylactoid reaction 
- Stevens-Johnson 
syndrome 
- Pancreatitis 
- Acute renal failure 
- Severe arthralgia 
Sodium-Glucose Co-
Transporter 2 (SGLT2) 
Inhibitors 
Canagliflozin 
Dapagliflozin 
empagliflozin 
 
 
 
- Inhibits sodium-glucose 
cotransporter 2 (SGLT2) 
- Reduces glucose reabsorption  
- Lowers renal glucose threshold 
(increases urinary glucose 
excretion) 
 
Precautions:  
- DKA 
- Volume depletion 
- eGFR<45 
Caution:  
- eGFR 45-59 
- concurrent nephrotoxic use 
- risk ketoacidosis 
- pancreatic insulin deficiency 
- prolonged fasting 
- alcohol abuse 
- hyperlipidemia 
- PMH genital mycotic infection, UTI 
- Uncircumcised males 
- UTI 
- URTI 
- Genital mycotic infections 
- Increased urination 
- Dyslipidemia 
- Increased hematocrit 
- Arthralgia 
- Nausea 
- Increased creatinine 
- Orthostatic hypotension 
- Renal impairment 
- Ketoacidosis 
- Serious UTI 
 
Glucagon-Like Piptide-
1 Agonists  
(GLP-1) 
Exenatide 
Liraglutide 
Albiglutide 
Dulaglutide 
- Activates GLP-1 receptors 
- Stimulates glucose dependent 
insulin release 
- Reduces glucagon secretion 
- Slows gastric emptying 
 
Precautions:  
- Hypersentivity 
- IM or IV administration 
- T1DM 
- DKA 
- PMH pancreatitis 
- CrCl <30 
Cautions:  
- Risk pancreatitis 
- Severe gastroparesis 
- Severe GI disease 
- Concurrent nephrotoxic agent use 
- Renal transplant 
- CrCl <50 
 
- Nausea 
- Vomit 
- Diarrhea 
- Hypoglycemia 
- Constipation 
- Headache 
- Dyspepsia 
- Hypersensitivity 
- Anaphylaxis 
- Nephrotoxicity 
- Pancreatitis 
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Aspirin 
 
- nonselective and irreversibly 
inhibits cyclooxygenase 
- reduces prostaglandin and 
thromboxane A2 synthesis 
- resultant anti-inflammatory, 
anti-pyretic effects, reduction 
of platelet aggregation 
 
Precautions:  
-  Hypersensitivity 
- ASA or NSAID induced asthma, 
urticarial 
- GI bleed 
- Disordered coagulation 
- G6PD deficiency 
- Uncontrolled hypertension 
- Influenza, varicella, or febrile viral 
infection in <20y/o 
Cautions:  
- ≥60y/o 
- Thrombocytopenia 
- Surgery 
- Trauma 
- Intracranial lesion 
- Increased intracranial pressure 
- Chronic alcohol use 
- Peptic ulcer disease 
- PMH GI bleed 
- GERD 
- Gout 
- Renal impairment 
- Hepatic impairment 
- Sodium restriction 
 
- Dyspepsia 
- Nausea 
- Vomit 
- Abdominal pain 
- Tinnitus 
- Dizziness 
- Hyperuricemia 
- Bleeding 
- Ecchymosis 
- Constipation 
- Diarrhea 
- Anaphylaxis 
- Angioedema 
- Bronchospasm 
- Bleeding 
- GI perforation/ulcer 
- DIC 
- Pancytopenia 
- Aplastic anemia 
- Agranulocytosis 
- Nephrotoxicity 
- Hepatotoxicity 
- Reye syndrome 
 
 
ACE-I - Inhibits angiotensin 
converting enzyme 
- Prevents conversion of 
angiotensin I into angiotensin 
II 
 
Precautions:  
-  Hypersensitivity 
- Angioedema (ACE-I, hereditary, 
idiopathic) 
- Pregnancy 
Cautions:  
- Renal artery stenosis 
- Renal impairment 
- Severe CHF 
- African American 
- Volume depletion 
- Hyponatremia 
- Hypotension 
- Aortic stenosis 
- Hypertrophic cardiomyopathy 
- CAD 
- Cerebrovascular disease 
- Collagen vascular disease 
- Dialysis with high flux membranes 
 
 
- Dizziness 
- Hypotension 
- Headache 
- Fatigue 
- Cough 
- Hyperkalemia 
- Elevated BUN, Cr 
- Photosensitivity 
- Hyperuricemia 
- Anaphylactoid reaction 
- Angioedema (head, neck, 
interstitial) 
- Stevens-Johnson 
syndrome 
- Toxic epidermal necrolysis 
- Erythema multiforme 
- Severe hypotension 
- Hyperkalemia 
- Renal impairment/failure 
- Hepatotoxicity 
- Neutropenia 
- Agranulocytosis 
- Pancreatitis 
- teratogenic 
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Statin - 3-hydroxy-3-methylglutaryl-
conenzyme A (HMG-COA) 
reductase inhibition 
 
Precautions:  
- Hypersensitivity 
- Pregnancy 
- Breastfeeding 
- Myopathy 
- Unexplained LFT elevations 
- Active hepatic disease  
Cautions:  
- Alcohol abuse 
- ≥65 y/o 
- Female 
- Renal impairment 
- PMH hepatic disease 
- Diabetes mellitus 
- hypothyroidism 
 
- Infection 
- CK elevations 
- Headache 
- Arthralgia 
- Sinusitis 
- Back pain 
- Flu syndrome 
- Pain 
- Flatulence 
- Myalgia 
- UTI 
- Abdominal pain  
- Diarrhea 
- Asthenia 
- Elevated ALT, AST 
- Decrease CoQ10 
- Hyperglycemia 
- Cognitive impairment 
- Myopathy 
- Rhabdomyolysis 
- Acute renal failure 
- Hepatotoxicity 
- Pancreatitis 
- Hypersensitivity 
- Anaphylaxis 
- Angioedema 
- Lupus erythematosus 
- Polymyalgia rheumatica 
- Dermatomyositis 
- Vasculitis 
- Thrombocytopenia 
- Leukopenia 
- Hemolytic anemia 
- Photosensitivity 
- Toxic epidermal necrolysis 
- Erythema multiforme 
- Stevens-Johnson 
syndrome 
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Table 3. 
Recommendations for Statin and Combination Treatment in Persons with Diabetes 
Risk Factors, by Age Recommended Statin Intensity* 
<40y  
None None 
ASCVD risk factors† Moderate or high (C rating) 
ASCVD High 
40-75y  
None Moderate (A rating) 
ASCVD risk factors High (B rating) 
ASCVD High 
ACS, LDL cholesterol level >1.3 mmol/L     (>50 mg/dL), and inability to 
tolerate high-dose statin therapy 
 
Moderate plus ezetimibe  
     (A rating) 
<75y  
None Moderate (B rating) 
ASCVD risk factors Moderate or high (B rating) 
ASCVD High 
ASCVD, LDL cholesterol level >1.3 mmol/L     (>50 mg/dL), and inability 
to tolerate high-dose statin therapy 
Moderate plus ezetimibe  
     (A rating) 
Note. ACS = acute coronary syndrome; ASCVD = atherosclerotic cardiovascular disease; LDL = low-density lipoprotein.  
* In addition to lifestyle therapy. 
† LDL cholesterol level ≥2.6 mmol/L (≥100 mg/dL), high blood pressure, smoking, overweight or obesity, and family 
history of premature ASCVD.  
 
Reprinted from “Diagnosis and Management of Diabetes: Synopsis of the 2016 American Diabetes Association 
Standards of Medical Care in Diabetes.” by J. J. Chamberlain, A. S. Rhinehart, C. F. Shaefer, and A. Neuman, 2016, 
Annals of Internal Medicine, 164, p. 547.  Copyright © 2016 American College of Physicians. 
 
 
 
Table 4. 
High- and Moderate-Intensity Statin Therapy* 
High-intensity 
Atorvastatin, 40-80 mg 
Rosuvastatin, 20-40 mg 
 
Moderate-intensity 
Atorvastatin, 10-20 mg 
Rosuvastatin, 5-10 mg 
Simvastatin, 20-40 mg 
Pravastatin, 40-80 mg 
Lovastatin, 40 mg 
Fluvastatin XL, 80 mg 
Pitastatin, 2-4 mg 
* Once-daily dosing. 
† Decreases low-density lipoprotein cholesterol level by ≥1.3 mmol/L (≥50 mg/dL). 
‡ Decreases low-density lipoprotein cholesterol lebel by 30% to <50%.   
 
Reprinted from “Diagnosis and Management of Diabetes: Synopsis of the 2016 American Diabetes Association Standards 
of Medical Care in Diabetes.” by J. J. Chamberlain, A. S. Rhinehart, C. F. Shaefer, and A. Neuman, 2016, Annals of Internal 
Medicine, 164, p. 548.  Copyright © 2016 American College of Physicians. 
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Table 5. 
Proposed pharmacodynamics and important patient safety related factors of other single herbs used to treat T2DM in TCM. 
 Mechanism of Action  Precautions Adverse Reactions 
Trichosanthis 
Radix 
 
Common name: 
Trichosanthes 
root; 
Chinese 
Cucumber 
(Tianhuafen) 
Not reported. Interacts with the following 
antihyperglycemic 
medications:  
- glimepiride  
- glyburide  
- insulin 
- pioglitazone  
- rosiglitazone 
- chlorpropamide  
- glipizide  
- tolbutamide  
- This herb should be used with 
caution during pregnancy. 
- Chinese cucumber ROOT 
contains a chemical that might 
cause abortions during the first 
trimester of pregnancy. 
- allergic reactions 
- seizures 
- fever 
- fluid retention (lungs, brain) 
- bleeding (brain) 
- heart damage and death 
- might lower blood sugar levels 
Astragali Radix 
 
Common name: 
Astragalus root 
(Huang qi) 
Not reported. - Decreases the effectiveness of 
Cyclophosphamide  
- Decreases lithium excretion 
- Decreases effectiveness of 
immunosupressants 
(azathioprine, basiliximab, 
cyclosporine, daclizumab, 
muromonab-CD3, 
mycophenolate, sirolimus, 
prednisone, corticosteroids) 
- Astragalus might make the 
immune system more active 
resulting in the  worsening of 
the symptoms of auto-immune 
diseases. 
Ligustri Lucidi 
Fructus 
Common name: 
Glossy privet 
fruit (Nuzhenzi) 
Not reported. Interaction: lithium -Glossy privet may cause an 
allergic reaction in people who 
are sensitive to the Oleaceae 
family of plants 
Ginseng Radix It is thought that ginseng 
contains a variety of chemicals 
called ginsenosides that are 
responsible for its effects. In 
herbal therapy, Ginseng is often 
used as an adaptogenic herb, 
which means that it can 
regulate a hypo or hyper 
functioning system. 
Interaction: 
- warfarin 
- alcohol 
- MAOIs 
- Furosemide  
- Insulin 
- anticoagulants 
- antiplatelet drugs 
- stimulants 
- drugs metabolized in the liver 
 
- thrombus formation  
- headache 
- tremor 
- mania 
- increased alcohol clearance 
-may worsen autoimmune 
diseases 
-interferes with blood clotting 
-might lower BP 
-linked with insomnia 
Corni Fructus  
Common name: 
Dogwood fruit 
(Shanzhuyu)  
Not reported None reported. -Deficiency of the liver and 
kidneys manifested as 
dizziness, blurred vision, 
soreness in the lower back, 
weakness of the legs, seminal 
emissions and impotence 
-Spontaneous sweating due to 
weakness of the body. 
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Figure 1. Antihyperglycemic therapy for type 2 diabetes mellitus: general recommendations. 
 
Figure 1. The order in the chart was determined by historical availability and the route of administration, with injectables 
to the right; it is nor meant to denote any specific preference.  Potential sequences of antihyperglycemic therapy for 
patient with type 2 diabetes mellitus are displayed, with the usual transition moving vertically from top to bottom 
(although horizontal movement within therapy stages is also possible, depending on the circumstances).   
* See Inzucchi et al. (2015) [80] for description of efficacy categorization.  
† Consider starting at this stage when the HbA1C level is 9% or greater.  
‡ Consider starting at this stage when blood glucose levels are 16.7 to 19.4 mmol/L (300 to 350 mg/dL) or greater and/or 
HbA1C levels are 10% to 12%, especially if symptomatic or catabolic features are present (in which case basal insulin plus 
mealtime insulin is the preferred initial regimen).   
§ Usually a basal insulin (neutral protamine Hagedorn, glargine, detemir, or degludec).  
 
Reprinted from “Diagnosis and Management of Diabetes: Synopsis of the 2016 American Diabetes Association Standards 
of Medical Care in Diabetes.” by J. J. Chamberlain, A. S. Rhinehart, C. F. Shaefer, and A. Neuman, 2016, Annals of Internal 
Medicine, 164, p. 546.  Copyright © 2016 American College of Physicians.  
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Figure 2.  A summary of the proposed mechanisms of antidiabetic effects of commonly utilized Traditional Chinese (TCM) and 
Indian Medicine (TIM) formulations and single herb ingredients alongside the established mechanisms of Traditional Modern 
Medicines (TMM). 
 
Figure 2. The numbered mechanisms of actions corresponding to those depicted above:  
Mechanism of Action TCM/TIM  TMM 
(1) Reduced carbohydrate absorption, such as inhibition of α-
glucosidase, α-amylase, and aldose reductase 
KQF N †   
GQT N † ‡ 
Metformin 
Acarbose 
(2) increased glucose uptake in muscle and adipose tissues RC N † ‡ Metformin 
Sulfonylureas 
Thiazolidinediones 
(3) activation of PPAR TM81 N  § 
GQT N † ‡ 
RS N § 
Thiazolidinediones 
 
(4) increased insulin sensitivity/ upregulation of receptor expression TM81 N  § 
RC N † ‡ 
RS N § 
Metformin 
(5) exertion of antioxidant effects and decreasing β-cell apoptosis  GQT N † ‡ 
RC N † ‡ 
 
(6) stimulation of β-cell insulin secretion TM81 N § 
KQF Y †   
GQT N † ‡ 
Metformin 
Sulfonylureas 
DPP-4 inhibitor 
GLP-1 receptor agonist 
(7) inhibition of hepatic gluconeogenesis/ glycogenolysis  Thiazolidinediones 
DPP-4 inhibitor 
(8) prevention of endogenous incretins from degradation/suppression 
of glucagon 
 DPP-4 inhibitor 
GLP-1 receptor agonist  
KQF: Kaiyu Qingre Fang (≥6 ingredients); TM81: Tang-Min-Ling-Wan (≥8 ingredients);  GQT: Gegen Qinlian Tang (≥6-12 ingredients); RC: 
Rhizoma Coptidis (single herb); RS: Radix Scutellariae (single herb); Tianqi (TCM, formulation reviewed but not listed in table above, 10 
ingredients) N †  ¥ U 
 
N No existing evidence of clinical research comparing efficacies   
Y Existing evidence of clinical research comparing efficacies   
   Proposed “similarity in efficacy” : 
       § not known or specified     † metformin/biguanides     ¥ α-glucosidase inhibitor     ‡ sulfonylureas  
U mechanism unknown or else not specified   
  
Adapted from “Treating type 2 diabetes mellitus with traditional Chinese and Indian medicinal herbs.” by A. Wang, J. Wang, and P. Chan, 
2013, Evidence-Based Complementary and Alternative Medicine, 2013, 343594.  Copyright © 2013 Zhijun Wang et al.  
 
